Lymphoma Clinical Trials in New York

Showing 501-520 of 727 trials

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

NCT02061449

This study evaluates the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the histone deacetylase inhibitor (HDACI) Romidepsin.

Cutaneous T-cell Lymphoma

NYU Langone Health3 participantsStarted Mar 2014

New York, New York, United States

COMPLETEDPhase 2< 1 mile

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

NCT00737529

To evaluate the safety and efficacy of Lenalidomide (Revlimid (R)) in subjects with mantle cell lymphoma who have relapsed, progressed or are refractory to bortezomib.

Mantle Cell Lymphoma

Celgene134 participantsStarted Dec 2008

Little Rock, Arkansas, United States • La Jolla, California, United States • Loma Linda, California, United States +67 more locations

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Lymphoma Trials in Other Cities

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma

A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

A Study of Enzastaurin in Participants With Follicular Lymphoma

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Other Conditions in New York